ABL209 (NEOK002) : Designing an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window [0.03%]
ABL209（NEOK002）：一种具有良好的抗肿瘤活性和增强的治疗窗口的EGFR×MUC1双特异拓扑异构酶1抑制剂抗体药物偶联物的设计
Bora Lee,Hyeon Ji Park,Byeong Min Yoo et al.
Bora Lee et al.
ABL209 (NEOK002) is a bispecific antibody-drug conjugate (ADC) designed to enhance efficacy and therapeutic window through dual targeting of EGFR and MUC1. Epidermal growth factor receptor (EGFR) is a key oncogenic driver in multiple tumor ...
ADCE-T02 - a Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability [0.03%]
下一代靶向组织因子的抗体药物偶联物ADCE-T02展现更佳的临床前有效性和耐受性
Thomas T Poulsen,Olga Ilina,Jonathan H Wardman et al.
Thomas T Poulsen et al.
Tissue factor (TF) protein is involved in activating the extrinsic blood coagulation cascade. TF expression is normally anatomically limited to the perivascular space, but TF is overexpressed in many malignancies, including pancreatic, cerv...
Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer [0.03%]
靶向染色质修饰酶KDM5C可增强ER阳性乳腺癌对AKT抑制的反应
Valentina Cutano,Shanade Dunn,Sungmi Park-Chouinard et al.
Valentina Cutano et al.
The AKT inhibitor capivasertib has demonstrated clinical benefit in combination with the selective ER degrader fulvestrant in PIK3CA, PTEN and AKT-1 altered estrogen receptor positive breast cancer (ER+ BC). A genome-wide CRISPR screen was ...
Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer [0.03%]
靶向NDUFS4扰乱氧化磷酸化并在奥拉帕利耐药的前列腺癌中诱导铁死亡
Zachary A Schaaf,Shu Ning,Amy R Leslie et al.
Zachary A Schaaf et al.
Resistance to PARP inhibitors (PARPi) remains a major challenge in the treatment of advanced prostate cancer. Although metabolic rewiring has been implicated in this process, the molecular drivers and therapeutic vulnerabilities underlying ...
Identification of CD74-positive antigen presenting glioma cells in primary human tumors and murine models of NF1 high-grade glioma [0.03%]
在NF1高分级胶质瘤原发性人类肿瘤和小鼠模型中鉴定CD74阳性抗原呈递胶质母细胞瘤细胞
Stephanie N Brosius,Jonathan H Sussman,Isabella A DiStefano et al.
Stephanie N Brosius et al.
Compared to the general population, individuals with Neurofibromatosis Type 1 have a 50-fold higher risk of developing a high-grade glioma (HGG) in their lifetime. Despite improved understanding of the molecular and cellular drivers of thes...
PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4 [0.03%]
PAMD-Ch17是一种plerixafor的聚合物类似物，可通过非CXCR4依赖性方式诱导T细胞急性淋巴细胞白血病(T-ALL)细胞线粒体功能障碍
Calvin Lam,Arjun Dhir,Arnob Mitro et al.
Calvin Lam et al.
PAMD-Ch17 is a polymer composed of the CXCR4 inhibitor AMD3100/Plerixafor with a cholesterol modification. In previous work, we showed that PAMD-Ch17, but not AMD3100, induces cell death and differentiation in mouse Acute Myeloid Leukemia c...
Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity [0.03%]
肽基天冬酰胺连接酶制备的抗体药物偶联物具有较强的体内外抗肿瘤活性
Abbas El Sahili,Siew Pheng Lim,Seetharamsing Balamkundu et al.
Abbas El Sahili et al.
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biopharmaceuticals for cancer targeted therapy, with fifteen ADCs approved for clinical use and over hundred candidates in clinical development. ADCs comprise a tumor-specific...
Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma [0.03%]
人源化高危神经母细胞瘤中肿瘤靶向纳米颗粒免疫治疗的急性清除和缓解T细胞衰竭作用
Griffin I Kane,Miranda B Diaz-Infante,Kim Wigglesworth et al.
Griffin I Kane et al.
Effective treatments for high-risk neuroblastoma, a pediatric malignancy with dismal survival outcomes, demand strategies that remodel the "cold" immunosuppressive tumor microenvironment (TME) to "hot" and proinflammatory. In this study, we...
Bortezomib Restores Venetoclax Sensitivity in Acute Myeloid Leukemia Cell Lines with Intrinsic and Acquired Resistance [0.03%]
硼替佐米恢复急性髓系白血病细胞系中内在和获得性耐药的维奈克拉敏感性
Chengxi Li,Yu-Hsuan Chang,Minori Maki et al.
Chengxi Li et al.
Venetoclax, a selective BCL-2 inhibitor, effectively induces apoptosis in a wide range of malignancies. Venetoclax-based regimens, combined venetoclax with either hypomethylating agents or low-dose cytarabine, have markedly improved treatme...
In-vivo analysis of neuroblastoma targeting potential of aGD2-SIRPα fusion antibodies for local CD47 blockade [0.03%]
基于SIRPα的aGD2-SIRPα融合抗体对神经母细胞瘤体内靶向作用的研究
Fabian Schuurmans,Matthia G M Boros,Renske J E van den Bijgaart et al.
Fabian Schuurmans et al.
Anti-GD2 monoclonal antibodies (aGD2 mAbs) are the standard immunotherapy for patients with high-risk neuroblastoma (NB). This treatment has improved 5-year overall survival, however, long-term efficacy still requires improvement. The don't...